Genzyme
Executive Summary
Announces public offering of 2.6 mil. shares of common stock prices at $13.125 per share. PaineWebber, Kidder Peabody and Cowen & Company are co-managing the offer. David McLachlan is new senior VP, chief financial officer and treasurer of the Boston, Massachusetts-based biotech company.